

Supporting Information

for

Bioactive selaginellins from *Selaginella tamariscina*

(Beauv.) Spring

Chao Yang ^{*1,2}, Yutian Shao ¹, Kang Li ¹ and Wujiong Xia ¹

Address: ¹ State Key Lab of Urban Water Resource and Environment & the Academy of Fundamental and Interdisciplinary Sciences, Harbin Institute of Technology, Harbin 150080, PR China and ² State Key Lab of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, PR China

Email: Chao Yang* - xyyang@hit.edu.cn

* Corresponding author

Spectroscopic data and other relevant information for compounds 1–4.

Table of Contents

Figure S1	^1H NMR (400 MHz, CD_3COCD_3) of compound 1	S3
Figure S2	^{13}C NMR (100 MHz, CD_3COCD_3) of compound 1	S3
Figure S3	^1H - ^1H COSY of compound 1	S4
Figure S4	HMQC of compound 1	S5
Figure S5	HMBC of compound 1	S6
Figure S6-S10	^1H , ^{13}C and 2D NMR spectra of compound 2	S7–S9
Figure S11-S15	^1H , ^{13}C and 2D NMR spectra of compound 3	S10–S12
Figure S16-S20	^1H , ^{13}C and 2D NMR spectra of compound 4	S13–S15
Table S1	Cytotoxic activity data for compounds 1–3	S16
Table S2	Antioxidant activity data for compounds 1–3	S16

Figure S1: ^1H NMR (400 MHz, CD_3COCD_3) of compound **1**




Figure S2: ^{13}C NMR (100 MHz, CD_3COCD_3) of compound **1**





Figure S3: ^1H - ^1H COSY of compound **1**



Selaginellin O





Figure S4: HMQC of compound **1**



Selaginellin O





Figure S5: HMBC of compound **1**



Selaginellin O




Figure S6: ^1H NMR (400 MHz, CD_3COCD_3) of compound **2**




Figure S7: ^{13}C NMR (100 MHz, CD_3COCD_3) of compound 2





Figure S8: ^1H - ^1H COSY of compound 2



Selaginellin M




Figure S9: HMQC of compound 2




Figure S10: HMBC of compound 2




Figure S11: ^1H NMR (400 MHz, CD_3COCD_3) of compound **3**




Figure S12: ^{13}C NMR (100 MHz, CD_3COCD_3) of compound **3**




Figure S13: ^1H - ^1H COSY of compound 3




Figure S14: HMQC of compound 3




Figure S15: HMBC of compound 3





Figure S16: ^1H NMR (400 MHz, CD_3COCD_3) of compound 4



Selaginellin A





Figure S17: ^{13}C NMR (100 MHz, CD_3COCD_3) of compound 4



Selaginellin A




Figure S18: ^1H - ^1H COSY of compound **4**




Figure S19: HMQC of compound 4




Figure S20: HMBC of compound 4




Table S1: Cytotoxic activity of compounds **1–3** evaluated with MTT assay.

Compounds	IC ₅₀ (μM ± SD) ^a
1	26.4 ± 0.80
2	28.5 ± 0.64
3	33.1 ± 1.21
Cisplatin ^b	15.4 ± 1.10

^aThe values represent means ± SD of three independent experiments^bPositive control**Table S2:** Antioxidant activity of compounds **1–3** evaluated with ABTS and FRAP assays^a

Compounds	ABTS assay	FRAP assay
	IC ₅₀ (μM ± SD)	Fe ^{II} (μmol/μmol ± SD)
1	2.94 ± 0.014	1.10 ± 0.058
2	3.02 ± 0.029	1.05 ± 0.056
3	3.07 ± 0.012	0.94 ± 0.050
Trolox ^b	5.23 ± 0.019	0.87 ± 0.043

^aValues are mean ± SD of three separated experiments.^bReference compound.